Roivant Sciences Ltd. (ROIV) Ownership
ROIV ownership summary
as of October 18, 2026- Institutions
- 78.4% of shares outstanding
- Insiders
- 21.42% of shares outstanding
- Shares outstanding
- 722.3M
- Float
- 581.9M shares available to trade
- Short interest
- 7.38% 39.3M shares short
- Days to cover
- 3.80 short interest up 8.6% vs prior month
- Institutions 78.38%
- Insiders 21.42%
- Other investors 0.20%
ROIV top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 11.22% | 81.0M | $2.72B | +3.0M (+3.9%) | June 30, 2026 |
| 2 | BlackRock Inc | 6.68% | 48.2M | $1.62B | +4.0M (+9.0%) | June 30, 2026 |
| 3 | Morgan Stanley - Brokerage Accounts | 5.90% | 42.6M | $1.43B | −9.2M (−17.8%) | June 30, 2026 |
| 4 | Qvt Financial LP | 3.28% | 23.7M | $795.4M | −1.4M (−5.7%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.06% | 22.1M | $741.8M | +1.4M (+7.0%) | June 30, 2026 |
| 6 | Vanguard Portfolio Management, LLC | 3.00% | 21.6M | $725.6M | +1.8M (+9.1%) | June 30, 2026 |
| 7 | The Goldman Sachs Group Inc | 2.57% | 18.6M | $622.2M | +7.4M (+67.0%) | June 30, 2026 |
| 8 | State Street Corp | 2.46% | 17.8M | $596.7M | +1.6M (+9.9%) | June 30, 2026 |
| 9 | UBS Group AG | 2.42% | 17.5M | $585.7M | −5.2M (−22.8%) | June 30, 2026 |
| 10 | Assenagon Asset Management SA | 2.32% | 16.7M | $560.8M | +9.6M (+136.4%) | June 30, 2026 |
| 11 | Farallon Capital Management, L.L.C. | 1.98% | 14.3M | $479.8M | +4.6M (+47.9%) | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 1.62% | 11.7M | $391.4M | +1.5M (+14.7%) | June 30, 2026 |
| 13 | Adage Capital Partners Gp LLC | 1.43% | 10.3M | $347.0M | −2.4M (−19.1%) | June 30, 2026 |
| 14 | Two Seas Capital LP | 1.29% | 9.3M | $312.8M | −463,600 (−4.7%) | March 31, 2026 |
| 15 | Perceptive Advisors LLC | 1.12% | 8.1M | $271.1M | −200,000 (−2.4%) | June 30, 2026 |
| 16 | Patient Square Capital LP | 1.11% | 8.0M | $268.9M | −145,119 (−1.8%) | June 30, 2026 |
| 17 | Amvescap Plc. | 1.04% | 7.5M | $252.5M | +1.1M (+17.0%) | June 30, 2026 |
| 18 | Darwin Global Management, Ltd. | 0.93% | 6.7M | $226.2M | −50,000 (−0.7%) | June 30, 2026 |
| 19 | AQR Capital Management LLC | 0.92% | 6.6M | $222.4M | +686,702 (+11.5%) | June 30, 2026 |
| 20 | Viking Global Investors LP | 0.87% | 6.3M | $210.3M | −380,981 (−5.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 36.9M shares and 9 cut 19.5M.
ROIV top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 3.19% | 23.0M | $771.5M | +35,000 (+0.2%) | August 31, 2026 |
| 2 | iShares Core S&P Mid-Cap ETF | 2.67% | 19.3M | $647.0M | −6,888 (−0.0%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.22% | 16.0M | $537.2M | −18,588 (−0.1%) | August 31, 2026 |
| 4 | Vanguard Small Cap Index | 1.60% | 11.6M | $388.5M | +12,313 (+0.1%) | August 31, 2026 |
| 5 | Invesco S&P MidCap Momentum ETF | 0.96% | 6.9M | $231.4M | — | September 30, 2026 |
| 6 | Fidelity Growth Company K6 | 0.92% | 6.7M | $223.6M | +10,100 (+0.2%) | August 31, 2026 |
| 7 | Vanguard MStar Small Cap Growth Indx Inv | 0.92% | 6.6M | $222.9M | −43,886 (−0.7%) | August 31, 2026 |
| 8 | Fidelity Series Growth Company | 0.78% | 5.6M | $187.9M | +93,700 (+1.7%) | August 31, 2026 |
| 9 | Morgan Stanley Inst Growth I | 0.73% | 5.3M | $177.2M | −178,186 (−3.3%) | June 30, 2026 |
| 10 | iShares Biotechnology ETF | 0.57% | 4.1M | $137.1M | −30,976 (−0.8%) | September 30, 2026 |
| 11 | MS INVF US Advantage I | 0.54% | 3.9M | $130.9M | −272,096 (−6.5%) | August 31, 2026 |
| 12 | State Street® SPDR® S&P® Biotech ETF | 0.49% | 3.6M | $119.3M | −67,700 (−1.9%) | September 30, 2026 |
| 13 | State Street® SPDR® S&P MIDCAP 400® ETF | 0.46% | 3.3M | $110.6M | −37,152 (−1.1%) | August 31, 2026 |
| 14 | Fidelity Contrafund | 0.45% | 3.2M | $108.8M | −1,135 (−0.0%) | August 31, 2026 |
| 15 | MS INVF US Growth I | 0.44% | 3.2M | $107.7M | −149,140 (−4.4%) | August 31, 2026 |
| 16 | Vanguard Explorer Inv | 0.44% | 3.2M | $107.0M | +1.2M (+59.4%) | June 30, 2026 |
| 17 | State Street SPDR Port S&P 400 Md CpETF | 0.40% | 2.9M | $96.0M | −4,024 (−0.1%) | September 30, 2026 |
| 18 | Pictet-Biotech P USD | 0.35% | 2.5M | $85.4M | +201,167 (+8.6%) | September 30, 2026 |
| 19 | Fidelity Extended Market Index | 0.30% | 2.2M | $73.5M | −22,871 (−1.0%) | August 31, 2026 |
| 20 | Harbor Capital Appreciation Instl | 0.30% | 2.2M | $72.7M | +2.2M (0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ROIV insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-20 | Eric Venker | Sell | $29.59 | 200,000 | $5.9M |
| 2026-04-16 | Matthew Gline | Sell | $29.16 | 289,774 | $8.4M |
| 2026-04-08 | Jennifer Humes | Sell | $28.37 | 13,538 | $384,073 |
| 2026-03-17 | Eric Venker | Sell | $28.24 | 200,000 | $5.6M |
| 2026-03-16 | Melissa B Epperly | Sell | $28.68 | 41,861 | $1.2M |
| 2026-02-23 | Frank Torti | Sell | $27.51 | 587,390 | $16.2M |
| 2026-02-20 | Frank Torti | Sell | $27.15 | 1,012,610 | $27.5M |
| 2026-02-19 | Frank Torti | Sell | $27.42 | 1,400,000 | $38.4M |
| 2026-02-13 | Daniel Allen Gold | Sell | $26.50 | 375,784 | $10.0M |
| 2026-02-13 | Eric Venker | Sell | $26.49 | 200,000 | $5.3M |
| 2026-02-11 | Daniel Allen Gold | Sell | $26.67 | 425,000 | $11.3M |
| 2026-02-09 | Mayukh Sukhatme | Sell | $26.47 | 339,441 | $9.0M |
| 2026-01-12 | Eric Venker | Sell | $21.92 | 200,000 | $4.4M |
| 2025-12-31 | Mayukh Sukhatme | Sell | $21.71 | 1,018,995 | $22.1M |
| 2025-12-29 | Mayukh Sukhatme | Sell | $21.74 | 311,873 | $6.8M |
| 2025-12-24 | Eric Venker | Sell | $22.53 | 75,000 | $1.7M |
| 2025-12-23 | Eric Venker | Sell | $22.45 | 200,000 | $4.5M |
| 2025-12-23 | Richard Pulik | Sell | $22.43 | 406,731 | $9.1M |
| 2025-12-17 | Daniel Allen Gold | Sell | $23.07 | 777,332 | $17.9M |
| 2025-12-17 | Mayukh Sukhatme | Sell | $23.09 | 26,831 | $619,528 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ROIV shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ROIV
Institutional investors own 78.4% of Roivant Sciences's shares and insiders 21.42%. The largest holder is FMR Inc with 11.22% of the shares (81.0M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 9 reduced their stake in the latest filings. Short interest is 7.38% of the float, or 3.80 days of average trading volume. The share count rose 1.8% since 2020.
Related: ROIV analyst forecast, ROIV key metrics. See the ROIV stock overview for the latest quote and news.
ROIV ownership FAQ
Who owns the most Roivant Sciences stock?
The largest shareholders of Roivant Sciences are FMR Inc (11.22%), BlackRock Inc (6.68%), Morgan Stanley - Brokerage Accounts (5.90%), Qvt Financial LP (3.28%), Vanguard Capital Management, LLC (3.06%).
What percentage of Roivant Sciences is owned by institutions?
Institutions hold 78.4% of Roivant Sciences's shares outstanding; insiders hold 21.42%.
Which funds own Roivant Sciences?
The largest fund holders of Roivant Sciences are Fidelity Growth Company Fund (3.19%), iShares Core S&P Mid-Cap ETF (2.67%), Vanguard MStar Total Stk Mkt Idx Invest (2.22%), Vanguard Small Cap Index (1.60%), Invesco S&P MidCap Momentum ETF (0.96%).
What is Roivant Sciences's short interest?
39.3M shares of Roivant Sciences were sold short, 7.38% of the float; at the average daily volume it would take 3.80 days to cover.
Are insiders buying or selling Roivant Sciences?
Of the latest 20 reported insider transactions in Roivant Sciences (since December 17, 2025), 0 were purchases and 20 were sales.
How many shares of Roivant Sciences are outstanding?
Roivant Sciences has 722.3M shares outstanding, of which 581.9M are in the public float.